{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:20:26Z","timestamp":1792632026402,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS090087"],"award-info":[{"award-number":["R21NS090087"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-11-029-01"],"award-info":[{"award-number":["RSG-11-029-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009075","name":"Bankhead-Coley Foundation","doi-asserted-by":"publisher","award":["Bankhead-Coley Cancer Research Program"],"award-info":[{"award-number":["Bankhead-Coley Cancer Research Program"]}],"id":[{"id":"10.13039\/100009075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009075","name":"Bankhead-Coley Foundation","doi-asserted-by":"publisher","award":["Cancer Research Seed Grant from Beaumont"],"award-info":[{"award-number":["Cancer Research Seed Grant from Beaumont"]}],"id":[{"id":"10.13039\/100009075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00262-019-02347-3","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T05:24:41Z","timestamp":1558589081000},"page":"1107-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma"],"prefix":"10.1007","volume":"68","author":[{"given":"Pravin","family":"Kesarwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"2347_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 19:v1\u2013v88. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox158","journal-title":"Neuro Oncol"},{"key":"2347_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","volume":"43","author":"SK Biswas","year":"2015","unstructured":"Biswas SK (2015) Metabolic reprogramming of immune cells in cancer progression. Immunity 43:435\u2013449. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2015.09.001","journal-title":"Immunity"},{"key":"2347_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"2347_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. \n                    https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"2347_CR5","doi-asserted-by":"publisher","first-page":"iii21","DOI":"10.1093\/neuonc\/nox036.071","volume":"19","author":"DA Reardon","year":"2017","unstructured":"Reardon DA, Omuro A, Brandes AA et al (2017) OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology 19:iii21. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox036.071","journal-title":"Neuro-Oncology"},{"key":"2347_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck MD, Sowell RT, Kaech SM, Pearce EL (2017) Metabolic instruction of immunity. Cell 169:570\u2013586. \n                    https:\/\/doi.org\/10.1016\/j.cell.2017.04.004","journal-title":"Cell"},{"key":"2347_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/neuonc\/nox079","volume":"19","author":"P Kesarwani","year":"2017","unstructured":"Kesarwani P, Kant S, Prabhu A, Chinnaiyan P (2017) The interplay between metabolic remodeling and immune regulation in glioblastoma. Neuro Oncol 19:1308\u20131315. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox079","journal-title":"Neuro Oncol"},{"key":"2347_CR8","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1158\/1078-0432.CCR-18-0041","volume":"24","author":"P Kesarwani","year":"2018","unstructured":"Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow KL, Wilson GD, Miller CR, Chinnaiyan P (2018) Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clin Cancer Res 24:3632\u20133643. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0041","journal-title":"Clin Cancer Res"},{"key":"2347_CR9","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","volume":"18","author":"DA Wainwright","year":"2012","unstructured":"Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110\u20136121. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2130","journal-title":"Clin Cancer Res"},{"key":"2347_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2014.00532","volume":"5","author":"M Rath","year":"2014","unstructured":"Rath M, Muller I, Kropf P, Closs EI, Munder M (2014) Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol 5:532. \n                    https:\/\/doi.org\/10.3389\/fimmu.2014.00532","journal-title":"Front Immunol"},{"key":"2347_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1101029","volume":"188","author":"P Kalinski","year":"2012","unstructured":"Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188:21\u201328. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1101029","journal-title":"J Immunol"},{"key":"2347_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmed.2015.11.003","volume":"22","author":"D Wang","year":"2016","unstructured":"Wang D, DuBois RN (2016) The role of prostaglandin E(2) in tumor-associated immunosuppression. Trends Mol Med 22:1\u20133. \n                    https:\/\/doi.org\/10.1016\/j.molmed.2015.11.003","journal-title":"Trends Mol Med"},{"key":"2347_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257\u20131265. \n                    https:\/\/doi.org\/10.1084\/jem.20062512","journal-title":"J Exp Med"},{"key":"2347_CR14","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-12-1572-T","volume":"72","author":"P Chinnaiyan","year":"2012","unstructured":"Chinnaiyan P, Kensicki E, Bloom G et al (2012) The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res 72:5878\u20135888. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1572-T","journal-title":"Cancer Res"},{"key":"2347_CR15","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1021\/ac901536h","volume":"81","author":"AM Evans","year":"2009","unstructured":"Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography\/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656\u20136667. \n                    https:\/\/doi.org\/10.1021\/ac901536h","journal-title":"Anal Chem"},{"key":"2347_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy185","author":"AH Prabhu","year":"2018","unstructured":"Prabhu AH, Kant S, Kesarwani P, Ahmed K, Forsyth P, Nakano I, Chinnaiyan P (2018) Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. Neuro Oncol. \n                    https:\/\/doi.org\/10.1093\/neuonc\/noy185","journal-title":"Neuro Oncol"},{"key":"2347_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/0008-5472.CAN-13-1423","volume":"74","author":"A Prabhu","year":"2014","unstructured":"Prabhu A, Sarcar B, Kahali S, Yuan Z, Johnson JJ, Adam KP, Kensicki E, Chinnaiyan P (2014) Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Res 74:787\u2013796. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1423","journal-title":"Cancer Res"},{"key":"2347_CR18","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.1221478110","volume":"110","author":"P Mao","year":"2013","unstructured":"Mao P, Joshi K, Li J et al (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 110:8644\u20138649. \n                    https:\/\/doi.org\/10.1073\/pnas.1221478110","journal-title":"Proc Natl Acad Sci USA"},{"key":"2347_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/neuonc\/not084","volume":"15","author":"M Vitucci","year":"2013","unstructured":"Vitucci M, Karpinich NO, Bash RE et al (2013) Cooperativity between MAPK and PI3\u00a0K signaling activation is required for glioblastoma pathogenesis. Neuro Oncol 15:1317\u20131329. \n                    https:\/\/doi.org\/10.1093\/neuonc\/not084","journal-title":"Neuro Oncol"},{"key":"2347_CR20","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2005-03-0979","volume":"106","author":"D Braun","year":"2005","unstructured":"Braun D, Longman RS, Albert ML (2005) A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106:2375\u20132381. \n                    https:\/\/doi.org\/10.1182\/blood-2005-03-0979","journal-title":"Blood"},{"key":"2347_CR21","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1128\/JVI.74.9.4110-4115.2000","volume":"74","author":"RS Grant","year":"2000","unstructured":"Grant RS, Naif H, Thuruthyil SJ, Nasr N, Littlejohn T, Takikawa O, Kapoor V (2000) Induction of indolamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J Virol 74:4110\u20134115","journal-title":"J Virol"},{"key":"2347_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457. \n                    https:\/\/doi.org\/10.1038\/nmeth.3337","journal-title":"Nat Methods"},{"key":"2347_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1172\/JCI21583","volume":"114","author":"DH Munn","year":"2004","unstructured":"Munn DH, Sharma MD, Hou D et al (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280\u2013290. \n                    https:\/\/doi.org\/10.1172\/JCI21583","journal-title":"J Clin Invest"},{"key":"2347_CR24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","volume":"281","author":"DH Munn","year":"1998","unstructured":"Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191\u20131193","journal-title":"Science"},{"key":"2347_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fimmu.2015.00034","volume":"6","author":"N van Baren","year":"2015","unstructured":"van Baren N, Van den Eynde BJ (2015) Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol 6:34. \n                    https:\/\/doi.org\/10.3389\/fimmu.2015.00034","journal-title":"Front Immunol"},{"key":"2347_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz CA, Litzenburger UM, Sahm F et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197\u2013203. \n                    https:\/\/doi.org\/10.1038\/nature10491","journal-title":"Nature"},{"key":"2347_CR27","doi-asserted-by":"publisher","first-page":"12689","DOI":"10.1038\/srep12689","volume":"5","author":"TD Hubbard","year":"2015","unstructured":"Hubbard TD, Murray IA, Bisson WH, Lahoti TS, Gowda K, Amin SG, Patterson AD, Perdew GH (2015) Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci Rep 5:12689. \n                    https:\/\/doi.org\/10.1038\/srep12689","journal-title":"Sci Rep"},{"key":"2347_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739\u2013744. \n                    https:\/\/doi.org\/10.1038\/nature08617","journal-title":"Nature"},{"key":"2347_CR29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"2347_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98\u2013110. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"key":"2347_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/neuonc\/nou369","volume":"17","author":"A Prabhu","year":"2015","unstructured":"Prabhu A, Sarcar B, Miller CR, Kim SH, Nakano I, Forsyth P, Chinnaiyan P (2015) Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro Oncol 17:1220\u20131230. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nou369","journal-title":"Neuro Oncol"},{"issue":"Pt 2","key":"2347_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1042\/bj3200595","volume":"320","author":"MP Heyes","year":"1996","unstructured":"Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP (1996) Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 320(Pt 2):595\u2013597","journal-title":"Biochem J"},{"key":"2347_CR33","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1158\/0008-5472.CAN-12-3831","volume":"73","author":"F Sahm","year":"2013","unstructured":"Sahm F, Oezen I, Opitz CA et al (2013) The endogenous tryptophan metabolite and NAD\u2009+\u2009precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res 73:3225\u20133234. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3831","journal-title":"Cancer Res"},{"key":"2347_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/414916a","volume":"414","author":"A Ohta","year":"2001","unstructured":"Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916\u2013920. \n                    https:\/\/doi.org\/10.1038\/414916a","journal-title":"Nature"},{"key":"2347_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1286-4579(03)00068-6","volume":"5","author":"M Thiel","year":"2003","unstructured":"Thiel M, Caldwell CC, Sitkovsky MV (2003) The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 5:515\u2013526","journal-title":"Microbes Infect"},{"key":"2347_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12967-016-1057-8","volume":"14","author":"Mora-Garcia M de Lourdes","year":"2016","unstructured":"de Lourdes Mora-Garcia M, Garcia-Rocha R, Morales-Ramirez O et al (2016) Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions. J Transl Med 14:302. \n                    https:\/\/doi.org\/10.1186\/s12967-016-1057-8","journal-title":"J Transl Med"},{"key":"2347_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","volume":"13","author":"RD Leone","year":"2015","unstructured":"Leone RD, Lo YC, Powell JD (2015) A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 13:265\u2013272. \n                    https:\/\/doi.org\/10.1016\/j.csbj.2015.03.008","journal-title":"Comput Struct Biotechnol J"},{"key":"2347_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.scr.2011.04.001","volume":"7","author":"F Saldanha-Araujo","year":"2011","unstructured":"Saldanha-Araujo F, Ferreira FI, Palma PV, Araujo AG, Queiroz RH, Covas DT, Zago MA, Panepucci RA (2011) Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res 7:66\u201374. \n                    https:\/\/doi.org\/10.1016\/j.scr.2011.04.001","journal-title":"Stem Cell Res"},{"key":"2347_CR39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/neuonc\/not067","volume":"15","author":"S Xu","year":"2013","unstructured":"Xu S, Shao QQ, Sun JT et al (2013) Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol 15:1160\u20131172. \n                    https:\/\/doi.org\/10.1093\/neuonc\/not067","journal-title":"Neuro Oncol"},{"key":"2347_CR40","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/neuonc\/nox100","volume":"19","author":"A Prabhu","year":"2017","unstructured":"Prabhu A, Kesarwani P, Kant S, Graham SF, Chinnaiyan P (2017) Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis. Neuro Oncol 19:1599\u20131606. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox100","journal-title":"Neuro Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02347-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:12:07Z","timestamp":1590016327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02347-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"GBM\/glioma tissue samples were obtained from the Moffitt Cancer Center Tissue Core Facility. Institutional Review Board\/Human Subjects approval (MCC16197) was obtained for this retrospective study from the ethics committee of the Moffitt Cancer Center. All animal studies were carried out under protocols approved by the IACUC (AL-16-09 and AL-18-10) at William Beaumont Research Institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients gave written informed consent for the use of their specimens and clinical data for research and publication prior to surgical resection or following diagnosis under the Total Cancer Care Tissue Repository program at the Moffitt Cancer Center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"C57BL\/6 (H-2b, CD45.2) and athymic nu\/nu (NU-<i>Foxn1<\/i><sup><i>nu<\/i><\/sup>) mice were purchased from Charles River Laboratories (Wilmington, MA).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"Human GBM cell lines U87, U251, and T98G were purchased from ATCC and authenticated by STR analysis at The University of Arizona Genetics Core. MES83, MES326, PN19, and PN84 were generated, obtained, and authenticated by Dr. Ichiro Nakano\u2019s lab at Ohio State University. Murine TRP cell lines were generated, obtained, and authenticated by Dr. C. Ryan Miller\u2019s lab at The University of North Carolina School of Medicine.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}